The Diagnostics Accelerator challenges the research community to develop cutting-edge biomarkers and explore novel diagnostic technologies that will aid in Alzheimer’s diagnosis and clinical trial design. Research funded to date focuses on various methods and targets including blood tests in various stages of development, as well as eye scans and digital tools.
These awards focus on true collaboration among renown clinicians, who are directly involved with patients and understand the disease, scientists who are developing the tests, and diagnostics companies that understand the regulatory pathways – driving research and product development.
Eligibility
Modalities: Blood and other peripheral markers, including saliva, urine, and ocular biomarkers are encouraged. The development of CSF and neuroimaging biomarkers will not be considered for this program; however, we encourage the use of these modalities to validate proposed biomarkers.
Biomarker targets: Proposed approaches will be evaluated on biological plausibility linking the biomarker to disease pathophysiology. Examples of target areas of interest include, but are not limited to:
- Vascular injury and blood-brain barrier integrity
- Neuroinflammation
- Neuroprotection and Neurodegeneration
- Biomarkers of interest in fronto-temporal degeneration (FTD)
- Protein misfolding
- Synaptic integrity and/or activity
- Mitochondria and metabolic function
Other novel approaches that are supported by compelling evidence that demonstrate a rational biological connection to the disease process are encouraged.
See Full Eligibility & Application Details